argenx (ARGX) vs Neurocrine Biosciences (NBIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
argenx (ARGX) has outperformed Neurocrine Biosciences (NBIX) over the past year, gaining 16.4% versus a gain of 4.7%. Over five years, ARGX leads with a +216.1% price change compared with +37.2% for NBIX. argenx is the larger company by market cap ($51.48 billion vs $14.36 billion), about 3.6 times the size.
On valuation, Neurocrine Biosciences trades at a lower forward P/E (11.9x vs 23.6x for argenx).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | NBIX |
|---|---|---|
| Share price | $818.63 | $141.25 |
| Market cap | $51.48B | $14.36B |
| 1-day change | -11.83% | -1.55% |
| YTD return | +10.40% | +1.16% |
| 1-year return | +16.44% | +4.72% |
| 5-year return | +216.08% | +37.24% |
| P/E ratio (TTM) | 31.20 | 20.71 |
| Forward P/E | 23.58 | 11.89 |
| EPS (TTM) | $26.24 | $6.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.86B |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $1.29B | $478.60M |
| Gross margin | — | 98.18% |
| Operating margin | — | 21.64% |
| Net margin | — | 16.73% |
| 52-week high | $1,072.75 | $186.12 |
| 52-week low | $661.85 | $122.14 |
| Distance from 52-week high | -23.69% | -24.11% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +43.17% | +46.75% |
| Average volume | 283.40K | 1.30M |
| Shares outstanding | 62.89M | 101.65M |
| Employees | 1,863 | 2,500 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- argenx is about 3.6 times larger than Neurocrine Biosciences by market value ($51.48B vs $14.36B).
- ARGX has outperformed NBIX by 11.7 percentage points over the past year.
- argenx trades at a higher earnings multiple (31.2x vs 20.7x trailing P/E).
- The two companies sit in different sectors: argenx in Healthcare and Neurocrine Biosciences in Health Care.
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Healthcare · Biotechnology · 1,863 employees
About Neurocrine Biosciences
NBIX stock →Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2,500 employees
ARGX vs NBIX FAQ
Which is bigger, argenx or Neurocrine Biosciences?
argenx (ARGX) is larger, with a market capitalization of $51.48B compared with $14.36B for Neurocrine Biosciences (NBIX).
Which stock has performed better over the past year, ARGX or NBIX?
ARGX returned +16.44% over the past 12 months, compared with +4.72% for NBIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or NBIX?
NBIX has the lower trailing P/E at 20.7, versus 31.2 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are argenx and Neurocrine Biosciences in the same industry?
No. argenx is in the Healthcare sector, while Neurocrine Biosciences is in Health Care.